Novo Nordisk, a Danish multinational pharmaceutical company, yesterday announced the positive trial results of its diabetes drug. In the trial, semaglutide demonstrated a safe and well-tolerated profile consistent with results from the SUSTAIN programme.
Semaglutide is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and food intake. Once-weekly semaglutide is currently under review by seven regulatory agencies, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency.
SUSTAIN is a clinical trial programme for semaglutide, administered once weekly, that comprises seven phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 8,000 adults with type 2 diabetes.
“The superior glucose control and weight loss achieved with semaglutide compared to dulaglutide in this trial reinforces the unprecedented results observed in the entire SUSTAIN programme” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “We are excited about the potential of semaglutide to set a new standard for treatment of type 2 diabetes”.